4//SEC Filing
INOTEK PHARMACEUTICALS CORP 4
Accession 0001209191-15-018745
$RCKTCIK 0001281895operating
Filed
Feb 24, 7:00 PM ET
Accepted
Feb 25, 6:11 PM ET
Size
17.9 KB
Accession
0001209191-15-018745
Insider Transaction Report
Form 4
Devon Park Associates, L.P.
10% Owner
Transactions
- Conversion
Common Stock
2015-02-23+2,323,610→ 2,323,610 total(indirect: See Footnotes) - Conversion
Convertible Promissory Notes
2015-02-23−626,942.9→ 0 total(indirect: See Footnote)→ Common Stock (105,933 underlying) - Purchase
Common Stock
2015-02-23$6.00/sh+814,166$4,884,996→ 3,243,709 total(indirect: See Footnotes) - Conversion
Common Stock
2015-02-23+105,933→ 2,429,543 total(indirect: See Footnotes) - Conversion
Series AA Convertible Preferred Stock
2015-02-23−7,432,720→ 0 total(indirect: See Footnote)→ Common Stock (2,323,610 underlying)
DEVON PARK BIOVENTURES LP
10% Owner
Transactions
- Conversion
Common Stock
2015-02-23+2,323,610→ 2,323,610 total(indirect: See Footnotes) - Conversion
Convertible Promissory Notes
2015-02-23−626,942.9→ 0 total(indirect: See Footnote)→ Common Stock (105,933 underlying) - Conversion
Common Stock
2015-02-23+105,933→ 2,429,543 total(indirect: See Footnotes) - Purchase
Common Stock
2015-02-23$6.00/sh+814,166$4,884,996→ 3,243,709 total(indirect: See Footnotes) - Conversion
Series AA Convertible Preferred Stock
2015-02-23−7,432,720→ 0 total(indirect: See Footnote)→ Common Stock (2,323,610 underlying)
Devon Park Associates, LLC
10% Owner
Transactions
- Conversion
Common Stock
2015-02-23+2,323,610→ 2,323,610 total(indirect: See Footnotes) - Purchase
Common Stock
2015-02-23$6.00/sh+814,166$4,884,996→ 3,243,709 total(indirect: See Footnotes) - Conversion
Series AA Convertible Preferred Stock
2015-02-23−7,432,720→ 0 total(indirect: See Footnote)→ Common Stock (2,323,610 underlying) - Conversion
Convertible Promissory Notes
2015-02-23−626,942.9→ 0 total(indirect: See Footnote)→ Common Stock (105,933 underlying) - Conversion
Common Stock
2015-02-23+105,933→ 2,429,543 total(indirect: See Footnotes)
Footnotes (4)
- [F1]Consists of the following shares of Common Stock issued upon conversion of shares of Series AA Convertible Preferred Stock ("Series AA") and accrued and unpaid dividends thereon, on a 4.05783-for-1 basis, upon the closing of the Issuer's initial public offering: 2,323,610 shares held directly by Devon Park Bioventures LP. The shares of Series AA had no expiration date.
- [F2]Securities are held directly by Devon Park Bioventures, LP. Devon Park Associates, LLC is the general partner of Devon Park Associates, L.P., which is the general partner of Devon Park Bioventures, LP. Messrs. Marc Ostro, Christopher Moller and Devang Kantesaria, a member of the Issuer's board of directors, are the founding members and managing members of Devon Park Associates, LLC. Each such managing member (the "Founding Member") may be deemed to have shared voting and investment power over the shares beneficially owned by Devon Park Bioventures, LP. Each Founding Member disclaims beneficial ownership of these securities, except to the extent of his pecuniary interest therein, and this report shall not be deemed an admission that the Founding Members are the beneficial owners of such securities for Section 16 or any other purpose.
- [F3]The outstanding principal amount and all accrued and unpaid interest under the Convertible Promissory Notes were automatically converted upon the closing of the Issuer's initial public offering into shares of Common Stock at the initial public offering price of $6.00 per share. The Convertible Promissory Notes had no expiration date. The number of shares of Common Stock as shown in column 4 of Table I consists of 105,933 shares held directly by Devon Park Bioventures LP.
- [F4]Consists of the following shares purchased at the Issuer's initial public offering: 814,166 shares held directly by Devon Park Bioventures LP.
Documents
Issuer
INOTEK PHARMACEUTICALS CORP
CIK 0001281895
Entity typeoperating
IncorporatedDE
Related Parties
1- filerCIK 0001281895
Filing Metadata
- Form type
- 4
- Filed
- Feb 24, 7:00 PM ET
- Accepted
- Feb 25, 6:11 PM ET
- Size
- 17.9 KB